Trevi Therapeutics

Trevi Therapeutics is a clinical-stage biopharmaceutical company developing treatments for uremic pruritus. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus and chronic cough in patients with idiopathic pulmonary fibrosis (IPF), as well as levodopa-induced dyskinesia (LID) in patients with Parkinson's disease.